|Articles|December 14, 2022

Understanding the true cost of transparency reporting

Author(s)PwC

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 22nd, 2026

Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma

Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.

October 22nd, 2026

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

October 21st, 2026

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.

The FDA cleared GSK’s bepirovirsen as add-on therapy for chronic hepatitis B, based on phase 3 trials in which 19% of patients reached functional cure. Credit: Stock.Adobe.com/Destina

October 21st, 2026

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.

October 21st, 2026

CSL Names Deborah Waterhouse as CEO and Manager Director

Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.

October 21st, 2026

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals

Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.

Understanding the true cost of transparency reporting

Related to this article

Trending on PharmExec

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

CSL Names Deborah Waterhouse as CEO and Manager Director

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals